

# A cross-sectional investigation into the association between *Porphyromonas gingivalis* and autoantibodies to citrullinated proteins in a German population

Oluwagbemigun, Kolade; Dietrich, Thomas

DOI:  
[10.1177/1759720X19883152](https://doi.org/10.1177/1759720X19883152)

License:  
Creative Commons: Attribution-NonCommercial (CC BY-NC)

*Document Version*  
Publisher's PDF, also known as Version of record

*Citation for published version (Harvard):*  
Oluwagbemigun, K & Dietrich, T 2019, 'A cross-sectional investigation into the association between *Porphyromonas gingivalis* and autoantibodies to citrullinated proteins in a German population', *Therapeutic Advances in Musculoskeletal Disease*, vol. 11. <https://doi.org/10.1177/1759720X19883152>

[Link to publication on Research at Birmingham portal](#)

## General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

## Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.

# A cross-sectional investigation into the association between *Porphyromonas gingivalis* and autoantibodies to citrullinated proteins in a German population

Kolade Oluwagbemigun<sup>ID</sup>, Tülay Yucel-Lindberg, Thomas Dietrich, Gregory Tour, Natalia Sherina, Monika Hansson, Manuela Bergmann, Karin Lundberg\* and Heiner Boeing\*

## Abstract

**Background:** *Porphyromonas gingivalis* (P.g) is unique among pathogens due to its ability to generate citrullinated proteins in an inflammatory milieu, potentially mediating the loss of immune tolerance, the production of anticitrullinated protein antibodies (ACPAs), and subsequently the development of rheumatoid arthritis (RA). Based on this hypothesis, we set out to investigate whether P.g is linked to ACPAs in a well-characterized German population.

**Participants and methods:** A total of 600 participants (292 women and 308 men with a mean age of 67 years) of the European Prospective Investigation into Cancer and Nutrition-Potsdam study were selected in 2013, and paired saliva and serum samples were collected. Salivary P.g DNA and serum anticyclic citrullinated peptide (anti-CCP2) levels were quantified by real-time polymerase chain reaction and anti-CCP2 enzyme-linked immunosorbent assay, respectively. In selected participants, additional ACPA fine-specificities were also analysed on a custom-made multiplex peptide array.

**Results:** Among participants with C-reactive protein greater than 3.0 mg/l, a one-unit increase in P.g DNA was associated with an almost twofold increase in anti-CCP2 levels. Moreover, participants with high P.g DNA had on average approximately 2.8-times higher anti-CCP2 levels when compared with participants with low P.g DNA, (Holm-adjusted *p* value = 0.01). Furthermore, citrullinated epitopes on  $\alpha$ -enolase and vimentin were common ACPA reactivities among participants who also had high P.g DNA and elevated C-reactive protein.

**Conclusions:** Our study suggests that in specific subgroups of individuals with systemic inflammation, higher salivary P.g DNA is associated with elevated serum ACPA. These data support a role for P.g in the development of anticitrulline immunity.

**Keywords:** anticitrullinated protein autoantibodies, C-reactive protein, population studies, *Porphyromonas gingivalis*, saliva, serum

Received: 4 July 2019; revised manuscript accepted: 26 September 2019.

## Introduction

Chronic periodontitis is arguably the most prevalent inflammatory disease affecting between 20% and 50% of adults worldwide.<sup>1-4</sup> Chronic periodontitis is the result of an aberrant host response to the oral microbial challenge in susceptible

individuals.<sup>5</sup> *Porphyromonas gingivalis* (P.g) is considered a key periodontal pathogen<sup>6</sup> and P.g infection is highly prevalent in patients with chronic periodontitis.<sup>7</sup> Chronic periodontitis and P.g infection have been hypothesized to contribute to the development of rheumatoid arthritis

*Ther Adv Musculoskel Dis*

2019, Vol. 11: 1-15

DOI: 10.1177/  
1759720X19883152

© The Author(s), 2019.  
Article reuse guidelines:  
sagepub.com/journals-  
permissions

Correspondence to:

**Kolade Oluwagbemigun**  
Nutritional Epidemiology,  
Department of Nutrition  
and Food Sciences,  
University of Bonn,  
Endericher Allee 19b,  
Bonn, 53115, Germany

Department of  
Epidemiology, German  
Institute of Human  
Nutrition, Potsdam-  
Nuthetal, Germany  
[koluwabg@uni-bonn.de](mailto:koluwabg@uni-bonn.de)

**Tülay Yucel-Lindberg**  
Periodontology Unit,  
Department of Dental  
Medicine, Karolinska  
Institutet, Stockholm,  
Sweden

**Thomas Dietrich**  
Department of Oral  
Surgery, School of  
Dentistry, University of  
Birmingham, Birmingham,  
UK

**Gregory Tour**  
Periodontology Unit,  
Department of Dental  
Medicine, Karolinska  
Institutet, Sweden

Department of Oral and  
Maxillofacial Surgery,  
Odense University  
Hospital, Denmark

**Natalia Sherina**  
**Monika Hansson**  
**Karin Lundberg**  
Rheumatology Unit,  
Department of Medicine,  
Karolinska Institutet,  
Stockholm, Sweden

**Manuela Bergmann**  
**Heiner Boeing**  
Department of  
Epidemiology, German  
Institute of Human  
Nutrition, Potsdam-  
Nuthetal, Germany

\*Shared senior authorship.

(RA).<sup>8</sup> In fact, chronic periodontitis and P.g infection were shown to be associated with the prevalence of RA in a systematic review.<sup>9</sup>

P.g has been suggested as an aetiological link due to its unique feature among prokaryotes to express an arginine-specific proteinase, referred to as peptidyl arginine deiminase enzyme (PPAD).<sup>10,11</sup> The aetiological hypothesis is that P.g, through the actions of PPAD and gingipains, directly initiates protein citrullination (deamination of arginine residues) of both host and bacterial proteins, generating neoepitopes at mucosal surfaces.<sup>11,12</sup> Continual spreading of neoepitopes and somatic hypermutation in genetically susceptible individuals eventually results in a breakdown of immune tolerance, upregulation of inflammatory responses, development of autoimmunity and the subsequent production of high-affinity antibodies to citrullinated proteins (ACPAs), a hallmark of RA.<sup>13,14</sup>

Local and systemic proinflammatory stimuli are essential for citrulline autoimmunity.<sup>15</sup> Indeed, citrullinated proteins and ACPAs are present in inflamed gingival tissue, suggesting local ACPA production, which may prime an individual for robust systemic ACPA production.<sup>16</sup> Observational epidemiological studies are commensurate with this hypothesis, in that higher ACPA titres were reported in the periodontium and serum of patients with periodontitis when compared with healthy controls.<sup>17,18</sup> A small clinical study also suggests that ACPA titres in patients with periodontitis may be specifically associated with oral exposure to P.g.<sup>19</sup> Previously, we have shown elevated anti-P.g antibody levels in patients with RA who are positive for ACPAs, compared with controls, and that these antibodies precede the clinical onset of RA.<sup>20,21</sup> This was confirmed in a meta-analysis.<sup>22</sup> Moreover, increased prevalence of periodontitis and P.g was shown recently in individuals at risk of being positive for ACPAs and unlike P.g, the abundance of another periodontal pathogen, *Aggregatibacter actinomycetemcomitans* was not increased in these individuals.<sup>23</sup> In addition, oral exposure of rodents to P.g was found to trigger seropositive arthritis.<sup>24</sup>

Most of the evidence linking P.g to ACPA is from patient groups and clinical cohorts, and very few are based on the general population. Therefore, we set out to evaluate the association between the presence of P.g in saliva and serum ACPA levels in a well-characterized population-based cohort of apparently healthy individuals.

## Participants and methods

### Study design and population


Our study population was participants of the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam study. Details of the study design, recruitment, and follow up of the EPIC-Potsdam participants have been described previously.<sup>25,26</sup> In brief, the EPIC-Potsdam participants were a cohort of 27,548 individuals, aged 35–64 years, who were recruited between 1994 and 1998 from the city of Potsdam, Germany and neighbouring communities. During this period, participants underwent baseline examinations, blood sampling, interviews, and completion of questionnaires about lifestyle characteristics and medical history. Every 2–3 years, questionnaires were sent to participants in order to obtain additional lifestyle and health data. All medical conditions at baseline and during follow up were medically verified. The Ethics Committee of the State of Brandenburg, Germany, approved the study and all participants provided informed consent.

Between 2010 and 2012, 1472 active participants were selected using a rectangular sampling scheme to ensure an approximately uniform sample spread across sex and three age groups (35–44, 45–54, and 55–64 years). All participants were invited to attend the study centre for specific clinical assessments. Of these participants, 815 (55%) responded to the invitation and consented to participate. These 815 participants were re-invited in 2013, and 728 (89%) consented. Paired blood and saliva samples were provided by 704 (97%) out of the 728 participants.

Unstimulated saliva was collected at the study centre in the morning using the PSP® (Pre-analytical Sample Processing) SalivaGene System kit (STRATEC Molecular GmbH, Berlin, and Germany) and processed. The sample collection, post-collection handling, processing, and storage of the samples were standardized. However, no presampling instructions were given to the participants. 30 ml of blood was also collected and processed. Both samples were stored at –80°C until laboratory analysis. A schematic description of the EPIC-Potsdam study in phases leading to the current study population is shown in Figure 1.

### Isolation of genomic DNA from saliva

Genomic DNA (gDNA) was isolated from saliva using the QIAamp DNA mini kit (QIAGEN AB,



**Figure 1.** Flow chart of the current study population.  
EPIC-Potsdam, European Prospective Investigation into Cancer and Nutrition-Potsdam.

Sollentuna, Sweden) according to the manufacturer's protocol. In brief, a 300- $\mu$ l aliquot of saliva was centrifuged at 10,000 r.p.m. for 15 min to pellet the sample. Then, 180  $\mu$ l of buffer ATL and 20  $\mu$ l of QIAGEN proteinase K were consecutively added to the pelleted sample. The mixture was vortexed and incubated at 56°C for 30 min, and purified using ethanol-containing buffers. The gDNA was eluted in nuclease-free water, followed by quantification and quality assessment (A260) with a NanoVue spectrophotometer (GE

Healthcare Bio-Sciences, Uppsala, Sweden) and stored at -20°C until analysis.

#### *Detection of P.g with quantitative real-time polymerase chain reaction*

Quantitative real-time polymerase chain reaction (qPCR) was performed on the gDNA using the universal primer 16S to detect the presence of nonspecific bacterial DNA and with P.g-specific primer to detect the presence of P.g. Duplicate

samples were assayed in a total volume of 20  $\mu$ l, containing 40 ng of the template gDNA solution, TaqMan Universal PCR Master Mix 2 $\times$  (Applied Biosystems, Carlsbad, USA), and the specific set of primers (final concentration 18  $\mu$ M) and probe (final concentration 5  $\mu$ M; Cybergene AB, Sweden). P.g primers were: forward –GCG CTC AAC GTT CAG CC; reverse: CAC GAA TTC CGC CTG C; and probe: 6FAM CAC TGA ACT CAA GCC CGG CAG TTT CAA–TAMRA, and the 16s rDNA (universal) were forward: TGG AGC ATG TGG TTT AAT TCG A; reverse –TGC GGG ACT TAA CCC AAC A; and probe: 6FAM CAC GAG CTG ACG ACA RCC ATG CA–TAMRA.<sup>27</sup>

The 7500 Fast Real-Time PCR System (Applied Biosystems) was used for amplification and detection of P.g. After an initial incubation step of 2 min at 50°C and denaturation for 10 min at 95°C, 40 PCR cycles (95°C for 15 s, 60°C for 1 min) were performed. The relative quantity of P.g was calculated as the fold difference in mean cycle threshold value of the P.g DNA relative to the mean cycle threshold value of the total bacterial DNA. DNA isolated from P.g strain ATCC 33277 was used as the positive control.

#### *Detection and quantification of ACPAs*

Serum samples were screened for the presence of ACPA immunoglobulin (Ig)G, using the Immunoscan CCPlus<sup>®</sup> enzyme-linked immunosorbent assay, from Euro-Diagnostica, Malmö, Sweden, according to the manufacturer's instructions. In addition, sera from participants with anti-CCP2 antibody levels  $\geq 25$  arbitrary units (AU)/ml (i.e. considered as anti-CCP2 antibody positive, according to the kit instructions) and an equal number of randomly selected participants with anti-CCP2 antibody levels  $< 25$  AU/ml (i.e. anti-CCP2 negative) were further analysed for the presence of ACPA fine-specificities using a custom-made microarray based on the ImmunoCAP ISAC microarray system (ThermoFisher Scientific, Phadia AB, Uppsala, Sweden), as previously described.<sup>28</sup> We investigated 10 citrullinated peptides derived from four different human proteins (fibrinogen, vimentin, filaggrin, and alpha-enolase) and 1 additional citrullinated peptide derived from PPAD, their arginine-containing control peptides, and 17 other autoantibody reactivities. The cut-off values for positivity (for each ACPA fine-specificity) were based on the 98th percentile cut-off among healthy controls. Supplemental Tables 1

and 2 provide details of the citrullinated and non-citrullinated antigens respectively.

#### *Measurement of serum markers of systemic inflammation*

Circulating levels of two markers of inflammation, C-reactive protein (CRP) and white blood cell (WBC; leukocyte) count, was measured. CRP was measured using a high-sensitivity immunoturbidimetric assay and expressed in mg/l. WBCs were measured by fluorescence flow cytometric method and expressed in Gpt/l.

#### *Assessments of covariates*

Information on sociodemographic characteristics, anthropometry, lifestyle, current medications (within 7 days), including antibiotics, nonsteroidal anti-inflammatory drugs (NSAIDs), and synthetic or biological disease-modifying antirheumatic drugs (DMARDs) were also reported. These covariates were ascertained with the use of questionnaire at baseline or during follow up. Importantly, participants were asked if they had ever been diagnosed with periodontitis and rheumatic diseases. These data are the status of the participants as of 2013. Details of covariates are available in supplemental text.

#### *Statistical analyses*

From the initial 704 individuals, we excluded 104 because of low gDNA levels that were insufficient for P.g quantification. There was no significant difference between these individuals and the 600 participants with sufficient gDNA (Supplemental Table 3). Using tertiles, 600 participants were categorized into three groups of low, moderate, and high P.g according to the relative quantity of P.g. For normally distributed continuous variables, non-normally distributed continuous variables, and categorical variables, one-way analysis of variance, Kruskal–Wallis nonparametric test, and Chi-square tests were used as statistical tests for differences across P.g groups, respectively.

We determined the relation between P.g and anti-CCP2 IgG by fitting Tweedie generalized linear models (details in supplemental text). The Tweedie generalized linear model is appropriate for modelling semicontinuous dependent variables<sup>29</sup> (anti-CCP2 IgG in the current study). Our independent variable, P.g fold difference was modelled in two ways: continuously and categorized into tertiles. At

first, we investigated whether the association between P.g and anti-CCP2 varied across subgroups of age, sex, body mass index, smoking status, periodontitis status, rheumatic diseases, CRP, and WBC count (details of subgroups in supplemental text) by including a product term between P.g and each variable in univariate analysis. Afterwards, we controlled for confounding by adjusting for covariates derived using directed acyclic graphs. Overall, we had four models: model 1 with P.g only, and three multivariable models (models 2–4; adjustment sets in supplemental text). The beta estimates were exponentiated as relative risk (RR). The RR of the continuously modelled P.g was interpreted unit change in anti-CCP2 associated with one-unit change in the fold difference of P.g. The categorically modelled P.g was interpreted as the ratio of the mean of anti-CCP2 between participants with either high or moderate P.g compared with the reference category, low P.g. These P.g group comparisons were adjusted for multiple comparisons using the Holm method. We also assessed the robustness of these analyses by excluding participants with myocardial infarction, stroke, and antibiotics, NSAID and DMARD use. Additionally, we investigated the nonlinear association between P.g and anti-CCP2 using restricted cubic spline regression adjusted for covariates in model 4. Anti-CCP2 was transformed using the Box–Cox method (details in supplemental text).

Finally, for each individual within the subsets of participants that were positive for anti-CCP2 and equal numbers of randomly selected participants who were negative for anti-CCP2, we reported the presence (and number) or absence of additional antibody reactivities, the number of ACPA/non-ACPA antibody reactivities, the quantity of P.g, CRP level, rheumatic disease, and the use of DMARDs or NSAIDs.

All statistical analyses were performed using SAS Enterprise Guide, version 6.1 (SAS Institute Inc., Cary, NC, USA). For all analysis,  $p \leq 0.05$  was considered statistically significant.

## Results

### *Characteristics of the study population*

The age range of the final study population ( $n=600$ , comprising 292 women and 308 men) was 47–82 years (mean age is 67 years with a standard deviation of 8.32). As shown in Table 1, across groups of increasing P.g, there was increasing sport

time, higher alcohol consumption, a higher prevalence of type 2 diabetes mellitus (T2DM), and a higher leucocyte count. Conversely, there was a lower proportion of higher-grade professionals. No difference was observed regarding other characteristics. Overall, 11 participants, corresponding to 2% of the study population, were positive for the anti-CCP2 antibody. The majority of the individuals who were positive for the anti-CCP2 antibody ( $n=6$ ) were found in the subset with a high P.g (Table 1).

### *Multivariable analyses of the association between quantity of P.g and anti-CCP2 IgG levels*

The interaction term of P.g (both as continuous and categorical variable) and CRP group on the continuously modelled dependent variable, anti-CCP2 IgG, was significant ( $p$  for interaction =  $<0.01$ ). This significant interaction term indicates that the association between P.g and anti-CCP2 IgG depends on CRP group. None of the interaction terms of P.g with other covariates were significant. Therefore, we fitted regression models separately for each CRP category and effect estimates, and RRs were presented as such. For each CRP category CCP2 model, the goodness of fit, Pearson's Chi-square statistic divided by the degrees of freedom was close to one (1.25 for CRP  $>3.0$  mg/l, 1.62 for CRP 1.0–3.0 mg/l, and 1.86 for CRP  $<1.0$  mg/l) showing that all specified CCP2 models fitted the data well.

Among participants with CRP  $>3.0$  mg/l, in the fully adjusted model, a one-unit increase in the fold difference of P.g was associated with an almost twofold increase in anti-CCP2 IgG levels. Moreover, when compared with participants with low P.g, participants with high P.g had on average approximately 2.8 times higher anti-CCP2 IgG levels [RR = 2.82; 95% confidence interval (CI): 1.60–9.11, Holm-adjusted  $p$  value = 0.01; Table 2]. Other covariates significantly associated with levels of anti-CCP2 IgG were smoking and education. Specifically, there was a threefold risk of elevated anti-CCP2 IgG levels among ever-smokers when compared with nonsmokers (RR = 3.24; 95% CI: 1.72–4.26,  $p = 0.01$ ), and a threefold risk of elevated anti-CCP2 IgG levels among those with technical school educational attainment when compared with those with a university degree (RR = 2.61; 95% CI: 1.23–3.72,  $p = 0.02$ ).

On the contrary, in groups of CRP 1.0–3.0 mg/l and CRP  $<1.0$  mg/l, there was no association between

**Table 1.** Characteristics of the study population (N=600).

	Quantity of <i>Porphyromonas gingivalis</i>			p value
	Low	Moderate	High	
Characteristics	(N=200)	(N=200)	(N=200)	
Women, N (%)	94 (47)	101 (51)	97 (49)	NS
Men, N (%)	106 (53)	99 (49)	103 (51)	NS
Age (years), M (SD)	67 (8.05)	67 (8.81)	67 (8.12)	NS
Body mass index (kg/m <sup>2</sup> ), M (SD)	27.38 (4.83)	27.22 (3.92)	27.56 (4.04)	NS
Vocational training or less, N (%)	76 (38)	68 (34)	69 (35)	NS
Higher-grade professionals, N (%)	56 (28)	54 (27)	47 (24)	<0.01
Sport (hours/week), M (SD)	4.74 (6.21)	5.18 (5.69)	5.44 (9.99)	0.04
Ever-smokers, N (%)	112 (56)	99 (50)	107 (54)	NS
Cigarettes/day <sup>a</sup> (N), M (SD)	11 (6.85)	11 (7.39)	9 (5.94)	NS
Alcohol (g/day), M (SD)	11.51 (15.43)	12.56(15.30)	13.06(16.54)	0.03
Periodontitis, N (%)	66 (33)	79 (40)	69 (35)	NS
Rheumatic diseases, N (%)	25 (13)	21 (11)	24 (13)	NS
Type 2 diabetes mellitus, N (%)	16 (8)	18 (9)	23 (12)	0.02
Myocardial infarction, N (%)	9 (5)	2 (1)	7 (4)	NS
Stroke, N (%)	3 (2)	5 (3)	5 (3)	NS
Cancer, N (%)	2 (1)	1 (1)	4 (2)	NS
DMARD, N (%)	8 (4)	3 (2)	9 (5)	NS
Antibiotics, N (%)	2 (1)	2 (1)	0 (0)	NS
NSAID, N (%)	24 (12)	15 (8)	26 (13)	NS
Leucocyte (Gpt/l), M (SD)	5.86 (1.46)	5.96 (1.52)	6.08 (1.56)	0.05
C-reactive protein (mg/l), M (SD)	3.32 (7.30)	2.77 (4.06)	2.79 (3.14)	NS
Anti-CCP2 IgG positive <sup>b</sup> , N (%)	3 (2)	2 (1)	6 (3)	NS

Anti-CCP2, second generation anticyclic citrullinated peptides antibody; AU, arbitrary units; DMARD, disease-modifying antirheumatic drug; ever-smokers, former smokers and current smokers; IgG, immunoglobulin G; M, mean; NS, nonsignificant at p value < 0.05; NSAID, nonsteroidal anti-inflammatory drug; P.g, *Porphyromonas gingivalis*; SD, standard deviation.

<sup>a</sup>Number of cigarettes of current smokers.

<sup>b</sup>Anti-CCP2 IgG ≥25AU/ml.

Detection of P.g DNA was performed using real-time PCR analysis. The relative quantity of P.g was calculated as the fold difference in mean cycle threshold value of the P.g DNA relative to the mean cycle threshold value of the total bacterial DNA. P.g quantity (fold difference) was categorized into low, moderate and high, according to tertiles.

continuously modelled P.g and anti-CCP2 antibody levels. Similarly, there was no difference between the moderate and high P.g when compared with low P.g (Table 2). In addition, no covariates

were significantly associated with levels of anti-CCP2 IgG in both groups. Further, there was no evidence of nonlinear associations between P.g and anti-CCP2 in both groups (Figures 2 and 3).


**Table 2.** Multivariable analyses of the association between quantity of P.g DNA and anti-CCP2 antibody levels.

		Anti-CCP2 IgG antibody levels (AU/ml)							
		Model 1		Model 2		Model 3		Model 4	
CRP		RR	95% CI	RR	95% CI	RR	95% CI	RR	95% CI
>3.0 mg/l (N= 151)	P.g (continuous)	4.07	1.96–8.46	2.54	1.32–4.86	1.98	1.12–3.39	1.99	1.15–3.40
	P.g (groups)	1.00	Ref.	1.00	Ref.	1.00	Ref.	1.00	Ref.
	Moderate (N=49)	1.37	0.51 to 3.67	1.38	0.56 to 3.40	1.26	0.59 to 2.70	1.34	0.61 to 2.96
	High (N=54)	8.02	3.05–21.10	4.92	1.98–12.23	3.26	1.45–7.31	2.82	1.60–9.11*
1.0–3.0 mg/l (N= 264)	P.g (continuous)	1.28	0.73–2.22	1.19	0.70–2.03	1.26	0.76–2.08	1.30	0.78–2.15
	P.g (groups)	1.00	Ref.	1.00	Ref.	1.00	Ref.	1.00	Ref.
	Moderate (N= 91)	1.05	0.51–2.14	1.02	0.50–2.05	1.12	0.58–2.19	1.14	0.59–2.23
	High (N=94)	1.55	0.76–3.16	1.40	0.69–2.82	1.42	0.72–2.80	1.49	0.74–2.97
< 1.0 mg/l (N= 185)	P.g (continuous)	0.88	0.54–1.44	0.87	0.53–1.42	0.79	0.45–1.33	0.76	0.45–1.30
	P.g (groups)	1.00	Ref.	1.00	Ref.	1.00	Ref.	1.00	Ref.
	Moderate (N= 60)	0.83	0.51–1.34	0.82	0.50–1.33	0.76	0.44–1.31	0.77	0.45–1.29
	High (N=52)	0.94	0.57–1.56	0.93	0.56–1.55	0.82	0.46–1.46	0.75	0.43–1.32


Model 1: unadjusted; model 2: model 1 adjusted for age (continuous), sex, body mass index (continuous); model 3: model 2 adjusted for education (three groups), occupation (four groups), work hours (six groups), hours of sport per week (continuous), alcohol (continuous), smoking status (two groups); model 4: model 3 adjusted for type 2 diabetes mellitus and cancer.

Anti-CCP2, second generation anticyclic citrullinated peptides antibody; AU, arbitrary unit; CI, confidence interval; CRP, C-reactive protein; IgG, immunoglobulin G; P.g, *Porphyromonas gingivalis*; Ref., reference; RR, relative risk.

\*Significantly different from low P.g. (Holm-adjusted *p* value = 0.02).



**Figure 2.** Restricted cubic spline regression graph to model nonlinear association among participants with CRP between 1.0 and 3.0 mg/l. Beta coefficient and 95% pointwise confidence band (dotted lines). Estimate was adjusted for age, sex, body mass index, education, occupation and work hours, smoking, alcohol, sport hours, type 2 diabetes mellitus, and cancer. Anti-CCP2 was transformed by a power of 0.08. The  $p$  value for nonlinear association was computed using the Wald Chi-square test. CCP2, cyclic citrullinated peptide; CRP, C-reactive protein; IgG, immunoglobulin G; P.g, *Porphyromonas gingivalis*.



**Figure 3.** Restricted cubic spline regression graph to model nonlinear association among participants with CRP < 1.0 mg/l. Beta coefficient and 95% pointwise confidence band (dotted lines). Estimate was adjusted for age, sex, body mass index, education, occupation and work hours, smoking, alcohol, sport hours, type 2 diabetes mellitus, and cancer. Anti-CCP2 was transformed by a power of 0.08. The  $p$  value for nonlinear association was computed using the Wald Chi-square test. CCP2, cyclic citrullinated peptide; CRP, C-reactive protein; IgG, immunoglobulin G; P.g, *Porphyromonas gingivalis*.

In sensitivity analyses, excluding participants with myocardial infarction, stroke and those who reported intake of antibiotics did not affect the results (data not shown). Moreover, excluding participants with CRP  $\geq 10.0$  mg/l (as a marker of acute inflammation) did not affect the results either. Interestingly, when we excluded all 11 individuals who were positive for anti-CCP2, as well as those using NSAIDs and DMARDs; there still were higher anti-CCP2 IgG levels among participants with high P.g when compared with those with low P.g, within the group with CRP > 3.0 mg/l.

#### *Comparison of individuals positive and negative for anti-CCP2 with respect to additional autoantibody reactivities*

Overall, 5 out of the 10 individuals who were positive for anti-CCP2 (1 was excluded due to

technical reasons) had at least one additional autoantibody reactivity, while 4 individuals out of the 11 randomly selected individuals who were negative for anti-CCP2 had at least one additional autoantibody reactivity (Table 3). Antibody reactivities corresponding to different ACPA fine-specificities were only detected in individuals who were positive for anti-CCP2. Antibodies against citrullinated  $\alpha$ -enolase (anti-CEP-1<sub>5-21</sub> IgG) and citrullinated vimentin (anti-Cit-Vim<sub>60-75</sub> IgG) constituted the most commonly detected ACPAs, and were present in four out of five individuals who were double positive for anti-CCP2/ACPA fine-specificity. Moreover, these four individuals also had a high quantity of P.g and high CRP levels (>3.0 mg/l). In addition, three out of the five individuals who were double positive for anti-CCP2/ACPA fine-specificity used DMARDs or NSAIDs, and three reported a rheumatic disease.

**Table 3.** Comparison of individuals positive for anti-CCP2 and randomly selected individuals negative for anti-CCP2.

Study participants	Additional autoantibody reactivities	anti-CCP2 (AU/ml)	Name of autoantibody (number of ACPAs versus non-ACPAs)	P.g quantity	Rheumatic diseases (yes/no)	CRP (mg/l)	DMARD (yes/no)	NSAID (yes/no)
<b>Anti-CCP2 positive (N= 10)</b>	Negative	27.24	None	Moderate	No	1.3	No	No
	Negative	33.01	None	Low	No	1.2	No	No
	Positive	567	Cit-Fil <sub>307-324</sub> , Cit-Vim <sub>60-75</sub> , Cit-Fib $\beta$ <sub>36-52</sub> , Cit-Fib $\alpha$ <sub>580-600</sub> , CEP-1 <sub>5-21</sub> (5/0)	High	No	3.8	No	No
	Positive	500.93	Cit-Vim <sub>60-75</sub> , Cit-Vim <sub>2-17</sub> , CEP-1 <sub>5-21</sub> , CPP-3 <sub>121-139</sub> (4/0)	High	No	4.1	Yes	No
	Negative	47.79	None	High	Yes	0.7	Yes	Yes
	Negative	57.21	None	Low	No	0.4	No	No
	Positive	63.28	Cit-Fil <sub>307-324</sub> (1/0)	Low	Yes	1.3	No	No
	Negative	43.28	None	Moderate	No	0.9	No	No
	Positive	129.87	Cit-Vim <sub>60-75</sub> , Cit-Fib $\beta$ <sub>[Cit-R]62-81a</sub> , CEP-1 <sub>5-21</sub> , CPP-3 <sub>121-139</sub> , dsDNA, U1 RNP-C (4/2)	High	Yes	18.5	Yes	Yes
	Positive	94.76	CEP-1 <sub>5-21</sub> , Cit-Vim <sub>60-75</sub> (2/0)	High	Yes	5.9	No	Yes
<b>Anti-CCP2 negative (N= 11)</b>	Negative	0	None	Low	No	16.0	No	Yes
	Positive	10.8	dsDNA (0/1)	Low	No	2.5	No	No
	Negative	0	None	Low	No	0.6	No	No
	Negative	0	None	Low	No	1.3	No	No
	Negative	0	None	High	No	4.8	No	No
	Positive	19.49	Ro60/SSA (0/1)	Moderate	No	3.9	No	No
	Negative	0	None	Moderate	No	0.7	No	No
	Positive	2.72	SmBB (0/1)	Moderate	No	2.9	No	No
	Negative	0	None	Low	No	11.9	No	No
	Negative	0	None	High	No	0.2	No	No
	Positive	0	dsDNA (0/1)	High	No	1.7	No	No

AU, arbitrary unit; CCP, cyclic citrullinated peptide; CEP, citrullinated  $\alpha$ -enolase peptide; Cit-Fib, citrullinated fibrinogen; Cit-Fil, citrullinated filaggrin; Cit-Vim, citrullinated vimentin; CRP, C-reactive protein; DMARD, disease-modifying antirheumatic drug; dsDNA, double-stranded DNA; NSAID, nonsteroidal anti-inflammatory drug; P.g, *Porphyromonas gingivalis*; Ro60/SSA, 60 kD RNA-associated protein; SmBB, small nuclear ribonucleoprotein-associated protein BB ribonucleoprotein; U1 RNP-C, human recombinant RNP-C protein.

One of these individuals was also positive for non-ACPA autoantibodies, directed against double-stranded DNA and U1 RNP-C complex protein. The individuals who were positive for anti-CCP2 and negative for the ACPA fine-specificities (CCP2<sup>+</sup>ACPA<sup>-</sup>) had relatively lower anti-CCP2 IgG levels compared with individuals who were positive for both anti-CCP2 and ACPA fine-specificities (CCP2<sup>+</sup>ACPA<sup>+</sup>). Moreover, individuals who were positive for anti-CCP2 'P.g high' when compared with individuals who were positive for anti-CCP2 'P.g low' generally had rheumatic disease, high CRP, and used DMARDs or NSAIDs (Table 3).

No ACPAs were detected among 11 randomly selected individuals who were negative for anti-CCP2. Antibody reactivities in this subset included double-stranded DNA, 60 kD RNA-associated protein, and small nuclear ribonucleoprotein-associated protein BB. In addition, none of these individuals reported a rheumatic disease or DMARD use (Table 3).

### Discussion

In this study of 600 individuals from a general population-based study cohort, we found a positive association between increasing quantity of salivary P.g DNA and serum anti-CCP2 IgG levels, after adjusting for various covariates. Specifically, this association was confined to individuals with systemic inflammation, CRP >3 mg/l. We also found that those individuals who were positive for a number of ACPA fine-specificities also demonstrated a higher quantity of salivary P.g and higher CRP levels when compared with individuals who were negative for ACPAs.

Our data demonstrating an association between P.g DNA and ACPAs support the aetiological hypothesis first proposed by Rosenstein and colleagues<sup>13</sup> that P.g infection plays a causative role in the development of ACPAs. This hypothesis was also supported by a number of other reports pinpointing a link between P.g infection and ACPA-positive RA. Some of these studies reported an association between the presence and abundance of P.g and anti-CCP2 antibodies,<sup>18</sup> while other studies,<sup>30–32</sup> including our recent publications<sup>20,21</sup> and a recent meta-analysis<sup>22</sup> reported a link between anti-P.g antibody levels and ACPAs, and yet others reported an association between clinical periodontitis and ACPAs.<sup>33–35</sup> Mikuls and colleagues<sup>30</sup> additionally reported an association

between anti-P.g antibody levels and CRP, suggesting that P.g infection influence both innate and adaptive immune responses. However, in other studies no relationship between anti-CCP2 and P.g abundance,<sup>36,37</sup> anti-P.g antibody levels,<sup>38,39</sup> and clinical periodontitis alone<sup>40</sup> was reported.

In relation to this ambiguity, elevated anti-CCP2 antibody levels were observed in patients with periodontitis and dental plaque P.g, as compared with patients with periodontitis without dental plaque P.g and healthy controls,<sup>18</sup> suggesting that the actual presence of P.g, rather than the severity of the periodontal lesion, is crucial in the relationship with ACPAs and ACPA-positive RA. This notion was also brought forward in our recent studies, where we were unable to identify a link between periodontitis and ACPA-positive RA,<sup>41</sup> but in the same RA cohort, we could demonstrate elevated anti-P.g antibody levels in ACPA-positive RA compared with both controls and ACPA-negative RA.<sup>20</sup> Based on data from these studies, we concluded that the previously reported link between periodontitis and RA could be accounted for by P.g infection. Moreover, it has been suggested that P.g infection contributes to the overall increase in ACPA seropositivity in individuals without RA.<sup>24,42,43</sup>

Importantly, the association between the presence of P.g DNA and higher serum anti-CCP2 antibody levels among individuals with high CRP in our study is noteworthy, given the evidence that P.g contributes to a systemic inflammatory milieu,<sup>44</sup> and that citrullination of proteins is known to occur in response to inflammation;<sup>15</sup> this may foster the generation of ACPAs in genetically susceptible individuals.<sup>14</sup> Our findings, with respect to the interplay between P.g and CRP on anti-CCP2 antibody, supports a recent review reporting the role of P.g and the proinflammatory profile among other factors in the association between periodontitis and RA.<sup>45</sup>

This provides insight into the mechanisms for the development of ACPAs. The low ACPA levels in one individual with high a quantity of salivary P.g DNA and high CRP levels might suggest a successful clearing of citrullinated proteins, and potentially the lack of genetic risk alleles (i.e. the HLA-DRB1 shared epitope), known to associate strongly with ACPA production.

Intriguingly, CEP-1 was one of the two most common ACPA fine-specificities among participants

with high P.g DNA. This supports previous findings that PPAD can citrullinate human  $\alpha$ -enolase,<sup>12</sup> and our previous report that anti-CEP-1 antibodies purified from RA patients bind citrullinated P.g enolase, forming the basis of a molecular mimicry hypothesis.<sup>11</sup> This hypothesis links P.g with RA *via* citrullination of enolase and ACPA production. Our CEP-1 data also support recent findings from another German population, that periodontitis patients with P.g infection have elevated anti-CEP-1 antibody levels.<sup>46</sup> Moreover, patients with RA with moderate to severe periodontitis and the presence of P.g have elevated anti-CEP-1 antibody levels compared with patients with RA without periodontitis or P.g.<sup>40</sup>

The proportion of individuals who were ACPA-positive in our study (1.8%) is similar to that reported from a large Swedish population-representative cohort (2.8%).<sup>47</sup> With a specificity and sensitivity of the anti-CCP2 assay of approximately 97% and 70%, respectively, and a Germany RA prevalence of 1.38%,<sup>48</sup> about 25% (4) of our study participants who were positive for anti-CCP2 antibody are expected to have RA, perhaps all four individuals who reported rheumatic disease. Specifically, the individuals who were double positive for anti-CCP2 and ACPA fine-specificity were likely suffering from RA, since a combination of ACPAs, use of DMARDs or NSAIDs, and high CRP are indicative of an RA diagnosis,<sup>49</sup> or 'pre-RA', since elevated anti-CCP2 are known to precede the development of RA.<sup>50</sup>

Furthermore, smoking is the main environmental risk factor for ACPA-positive RA,<sup>51</sup> and the association between smoking and elevated anti-CCP2 antibody levels as seen in our study is also a well-known phenomenon in 'pre-RA'.<sup>52</sup> Studies that reported a relation between lower educational level and anti-CCP2 antibodies is scarce. However, lower socioeconomic status because of lower educational attainment has been postulated to influence the risk of RA.<sup>53</sup> Consistent with our findings on factors related to the quantity of P.g, others have documented that individuals who have a higher alcohol intake harbour more P.g,<sup>54</sup> individuals with T2DM have a high quantity of salivary P.g,<sup>55</sup> and P.g infection induces local and systemic accumulation of leucocytes.<sup>56</sup> Aside from poor oral health that is generally observed in athletes<sup>57</sup> and the relation between educational level and P.g,<sup>58</sup> the association of P.g with sport activity and occupation has not been previously reported. Possible explanation for these

determinants of P.g are alcohol consumption resulting in dysbiosis,<sup>54</sup> dehydration and local drying of the mouth during sporting activity reducing antimicrobial activity in the mouth<sup>57</sup> and systemic diseases weakening resistance to infection and altering inflammatory response.<sup>59</sup>

A previous study<sup>60</sup> did not observe difference in individuals with P.g with RA compared with controls. One possible explanation for the contrasting results of Zhang and colleagues<sup>60</sup> is the discrepant detection of P.g that is related to age.<sup>58,61</sup> Our study population (average age of 67 years) is older than that of Zhang and colleagues (the highest age was 65 years and the average age was not reported)<sup>60</sup> and since saliva P.g increases with age;<sup>58,61</sup> it is likely that the more detectable P.g in our study population partly results in association with anti-CCP2/RA.

The strengths of our study were that participants were selected with special consideration for sex and age strata and were thus representative of a well-characterized population of apparently healthy individuals. In addition, both exposure and outcome were measured objectively, that is, in biological samples. Moreover, compared with P.g detection from dental plaque or another oral niche, salivary P.g captures an aggregate of overall P.g exposure, because P.g and other oral bacteria are continually shed into the saliva from all ecological sites. This study adjusted for several factors such as age, sex, smoking, health conditions, and medications, which might have confounded our results.

Nevertheless, some points have to be taken into account when interpreting our findings. The participants' physicians verified most chronic diseases in the EPIC-Potsdam study, but periodontitis and rheumatic diseases were not verified because the EPIC-Potsdam study was not primarily designed to investigate dental health and rheumatic diseases. Hence, detailed information, such as dental hygiene practices, periodontal care, specific types of rheumatic disease and their duration were not available. Nevertheless, most of the covariates and confounders that were considered in the analysis were verified. In addition, the absence of an association between the quantity of P.g and periodontitis could be due the fact that periodontitis was self-reported and the poor validity of self-reported periodontitis, which is well documented,<sup>62</sup> and could also be explained in part by the fact that periodontitis is a

polymicrobial infection and that *P.g* might be absent in some individuals with periodontitis. When sampling saliva, participants are often instructed not to eat, drink, smoke, or chew gum or perform oral hygiene for 30 min prior to sampling. These instructions were not given to our participants and these factors might have affected yields of gDNA and hence the quantity of *P.g*. However, the fact that gDNA was not significantly associated with quantity of *P.g* in the current study, and considering that these factors are unlikely to affect CCP2 IgG levels suggest that they cannot confound the association between *P.g* and ACPA. Nonetheless, future studies should endeavour to standardize saliva presampling, sampling, and postsampling procedures. Another drawback is that we did not specifically ask participants for RA diagnosis, but 'rheumatic diseases', which comprise an array of diseases. Rheumatoid factor, another important RA biomarker was not measured in this study. Additional reactivity to fine-specific ACPAs could have been determined in all (or larger number of) samples, but this was not feasible due to logistic reasons.

A further limitation of our study was its cross-sectional design. One would expect time lags between the colonization of *P.g*, onset of *P.g* infection, and the development of antibodies to citrullinated proteins,<sup>31</sup> therefore elevated ACPAs may reflect the action of past *P.g* infection only or in consort with present infections. Surely, serum IgG to virulence factors in *P.g* such as arginine-specific gingipain B or outer membrane antigen may be a more suitable marker of both present and past *P.g* infection. The homogenous German study population may limit generalizability of this current study to other nationalities or ethnic groups, although our findings are similar to reports in other populations.<sup>30</sup> Furthermore, we cannot rule out residual and unmeasured confounders of the association between *P.g* and ACPAs, such as levels of total IgG. In addition, we did not control for confounding between CRP and ACPAs since our primary interest was to assess the relation of *P.g* DNA with ACPA levels. Moreover, reverse causation due to RA was unlikely in the relation of *P.g* with CCP2 IgG levels since we excluded participants using DMARDs as proxy for RA in sensitivity analysis. The focus of this study was to investigate the association between salivary *P.g* and serum ACPA levels; hence, we did not perform measurements of anti-*P.g* antibodies in our participants. The measurement of anti-*P.g* antibodies levels and investigation

of their relation to *P.g* abundance is planned for future studies.

Within the limits of our study, salivary *P.g* DNA was linked to serum anti-CCP2 in the presence of systemic inflammation, and individuals who were anti-CCP2 positive showed additional reactivity to fine-specific ACPAs. Individuals with double positive anti-CCP2 and ACPA fine-specificity also had high *P.g* and were likely suffering from RA. Longitudinal multicentre studies with larger study populations to investigate the relationship between *P.g* colonization and infection and ACPAs are warranted.

### Acknowledgements

We thank the staff of the Human Study Centre of the German Institute of Human Nutrition Potsdam-Rehbrücke, Germany, namely of the trustee and the examination unit for the data collection, of the data hub for the processing, and of the Biobank for the processing of the blood samples. We thank the participants of the EPIC-Potsdam study for the provision of their data and biological samples. We also acknowledge the valuable help of Jana Foerster and the text-editing support of Friederike Querengässer.

Kolade Oluwagbemigun (KO), Tülay Yucel-Lindberg (TY), Karin Lundberg (KL), Manuela Bergmann (MB), and HB (Heiner Boeing) designed the current study. KO, TY, and Gregory Tour isolated genomic DNA from saliva and detection of *P.g*. KO, Natalia Sherina (NS), and KL screened participants for anti-CCP2. Monika Hansson and KL screened participants for other ACPA fine-specificities. KO, TY, and KL analysed and interpreted the data. KO was the main contributor in writing the manuscript. TY, KL, NS, Thomas Dietrich, MB and HB revised the manuscript. All authors read and approved the final manuscript. KL and HB share senior authorship.

The Ethics Committee of the State of Brandenburg, Germany, approved the study and all participants provided informed consent. Consent forms of the participants are available at the Human Study Centre of the German Institute of Human Nutrition, Potsdam-Nuthetal, Germany. The datasets analysed during the current study are not publicly available, but are available from the corresponding author on reasonable request.

### Funding

The authors disclosed receipt of the following financial support for the research, authorship,

and/or publication of this article: The recruitment part of the EPIC-Potsdam study, Germany was supported by the German Federal Ministry of Science, Bonn, Germany (01 EA 9401) and the European Union (EU), Brussels, Belgium (SOC 95201408 05F02), while the follow up of the EPIC-Potsdam Study was supported by the German Cancer Aid, Bonn, Germany (70–2488–Ha I) and the European Community (now EU), Brussels, Belgium (SOC 98200769 05F02). The work concerning P.g and autoantibodies to citrullinated proteins analyses was supported by grants from the EU-funded ITN project RAPID (290246), the EU-funded FP7 project TRIGGER (FP7-Health-2013-306029), Swedish Research Council, and Stockholm County Council. KO is currently supported by the Federal Ministry of Education and Research, Germany (grant number: 01EA1705A) through the European Joint Programming Initiative ‘A Healthy Diet for a Healthy Life’ project, Metabolic HEALTH through nutrition, microbiota and tryptophan bioMARKers (HEALTHMARK). The funders had no influence on the current study, as regards its design, analysis of data, decision to publish, and preparation of the manuscript.

### Conflict of interest statement

The authors declare that there is no conflict of interest.

### ORCID iD

Kolade Oluwagbemigun  <https://orcid.org/0000-0002-9454-5970>

### Supplemental material

Supplemental material for this article is available online.

### References

- Micheelis W, Hoffmann T, Holtfreter B, *et al.* Zur epidemiologischen Einschätzung der Parodontitislast in Deutschland–Versuch einer Bilanzierung. *Deutsche Zahnärztliche Zeitschrift* 2008; 63: S464–S472.
- Sanz M, D’aiuto F, Deanfield J, *et al.* European workshop in periodontal health and cardiovascular disease-scientific evidence on the association between periodontal and cardiovascular diseases: a review of the literature. *Eur Heart J Suppl* 2010; 12: B3–B12.
- Chapple IL. Time to take periodontitis seriously. *BMJ* 2014; 348: 2645.
- Eke PI, Dye BA, Wei L, *et al.* Update on prevalence of periodontitis in adults in the United States: NHANES 2009 to 2012. *J Periodontol* 2015; 86: 611–622.
- Yucel-Lindberg T and Båge T. Inflammatory mediators in the pathogenesis of periodontitis. *Expert Rev Mol Med* 2013; 15: e7.
- Darveau RP, Hajishengallis G and Curtis MA. *Porphyromonas gingivalis* as a potential community activist for disease. *J Dent Res* 2012; 91: 816–820.
- Loesche WJ and Grossman NS. Periodontal disease as a specific, albeit chronic, infection: diagnosis and treatment. *Clin Microbiol Rev* 2001; 14: 727–752.
- Hoovestol RA and Mikuls TR. Environmental exposures and rheumatoid arthritis risk. *Curr Rheumatol Rep* 2011; 13: 431–439.
- Kaur S, White S and Bartold PM. Periodontal disease and rheumatoid arthritis: a systematic review. *J Dent Res* 2013; 92: 399–408.
- McGraw WT, Potempa J, Farley D, *et al.* Purification, characterization, and sequence analysis of a potential virulence factor from *Porphyromonas gingivalis*, peptidylarginine deiminase. *Infect Immun* 1999; 67: 3248–3256.
- Lundberg K, Kinloch A, Fisher BA, *et al.* Antibodies to citrullinated alpha-enolase peptide 1 are specific for rheumatoid arthritis and cross-react with bacterial enolase. *Arthritis Rheum* 2008; 58: 3009–3019.
- Wegner N, Wait R, Sroka A, *et al.* Peptidylarginine deiminase from *Porphyromonas gingivalis* citrullinates human fibrinogen and  $\alpha$ -enolase: implications for autoimmunity in rheumatoid arthritis. *Arthritis Rheum.* 2010; 62: 2662–2672.
- Rosenstein ED, Greenwald RA, Kushner LJ, *et al.* Hypothesis: the humoral immune response to oral bacteria provides a stimulus for the development of rheumatoid arthritis. *Inflammation* 2004; 28: 311–318.
- Lundberg K, Wegner N, Yucel-Lindberg T, *et al.* Periodontitis in RA-the citrullinated enolase connection. *Nat Rev Rheumatol* 2010; 6: 727–730.
- Demoruelle MK, Deane KD and Holers VM. When and where does inflammation begin in rheumatoid arthritis? *Curr Opin Rheumatol* 2014; 26: 64–71.
- Harvey GP, Fitzsimmons TR, Dhamarpatni AA, *et al.* Expression of peptidylarginine deiminase-2 and -4, citrullinated proteins and anti-citrullinated protein antibodies in human gingiva. *J Periodontal Res* 2013; 48: 252–261.

17. Nesse W, Westra J, van der Wal JE, *et al.* The periodontium of periodontitis patients contains citrullinated proteins which may play a role in ACPA (anti-citrullinated protein antibody) formation. *J Clin Periodontol* 2012; 39: 599–607.
18. Mikuls TR, Payne JB, Yu F, *et al.* Periodontitis and *Porphyromonas gingivalis* in patients with rheumatoid arthritis. *Arthritis Rheumatol* 2014; 66: 1090–1100.
19. Lappin DF, Apatzidou D, Quirke AM, *et al.* Influence of periodontal disease, *Porphyromonas gingivalis* and cigarette smoking on systemic anti-citrullinated peptide antibody titres. *J Clin Periodontol* 2013; 40: 907–915.
20. Kharlamova N, Jiang X, Sherina N, *et al.* Antibodies to *Porphyromonas gingivalis* indicate interaction between oral infection, smoking, and risk genes in rheumatoid arthritis etiology. *Arthritis Rheumatol* 2016; 68: 604–613.
21. Johansson L, Sherina N, Kharlamova N, *et al.* Concentration of antibodies against *Porphyromonas gingivalis* is increased before the onset of symptoms of rheumatoid arthritis. *Arthritis Res Ther* 2016; 18: 201.
22. Bae SC and Lee YH. Association between anti-*Porphyromonas gingivalis* antibody, anti-citrullinated protein antibodies, and rheumatoid arthritis: a meta-analysis. *Z Rheumatol* 2018; 77: 522–532.
23. Mankia K, Cheng Z, Do T, *et al.* Prevalence of periodontal disease and periodontopathic bacteria in anti-cyclic citrullinated protein antibody-positive at-risk adults without arthritis. *JAMA Netw Open* 2019; 2: e195394.
24. Courbon G, Rinaudo-Gaujous M, Blasco-Baque V, *et al.* *Porphyromonas gingivalis* experimentally induces periodontitis and an anti-CCP2-associated arthritis in the rat. *Ann Rheum Dis* 2019; 78: 594–599.
25. Boeing H, Wahrendorf J and Becker N. EPIC-Germany—a source for studies into diet and risk of chronic diseases. European investigation into cancer and nutrition. *Ann Nutr Metab* 1999; 43: 195–204.
26. Bergmann MM, Bussas U and Boeing H. Follow-up procedures in EPIC-Germany—data quality aspects. European prospective investigation into cancer and nutrition. *Ann Nutr Metab* 1999; 43: 225–234.
27. Boutaga K, van Winkelhoff AJ, Vandenbroucke-Grauls CM, *et al.* Comparison of real-time PCR and culture for detection of *Porphyromonas gingivalis* in subgingival plaque samples. *J Clin Microbiol* 2003; 41: 4950–4954.
28. Hansson M, Mathsson L, Schleder T, *et al.* Validation of a multiplex chip-based assay for the detection of autoantibodies against citrullinated peptides. *Arthritis Res Ther* 2012; 14: R201.
29. Kurz CF. Tweedie distributions for fitting semicontinuous health care utilization cost data. *BMC Med Res Methodol* 2017; 17: 171.
30. Mikuls TR, Payne JB, Reinhardt RA, *et al.* Antibody responses to *Porphyromonas gingivalis* (*P. gingivalis*) in subjects with rheumatoid arthritis and periodontitis. *Int Immunopharmacol* 2009; 9: 38–42.
31. Hitchon CA, Chandad F, Ferucci ED, *et al.* Antibodies to *Porphyromonas gingivalis* are associated with anti-citrullinated protein antibodies in patients with rheumatoid arthritis and their relatives. *J Rheumatol* 2010; 37: 1105–1112.
32. Mikuls TR, Thiele GM, Deane KD, *et al.* *Porphyromonas gingivalis* and disease-related autoantibodies in individuals at increased risk of rheumatoid arthritis. *Arthritis Rheum* 2012; 64: 3522–3530.
33. Hendler A, Mulli TK, Hughes FJ, *et al.* Involvement of autoimmunity in the pathogenesis of aggressive periodontitis. *J Dent Res* 2010; 89: 1389–1394.
34. Dissick A, Redman RS, Jones M, *et al.* Association of periodontitis with rheumatoid arthritis: a pilot study. *J Periodontol* 2010; 81: 223–230.
35. Terao C, Asai K, Hashimoto M, *et al.* Significant association of periodontal disease with anti-citrullinated peptide antibody in a Japanese healthy population - The Nagahama study. *J Autoimmun* 2015; 59: 85–90.
36. Scher JU, Ubeda C, Equinda M, *et al.* Periodontal disease and the oral microbiota in new-onset rheumatoid arthritis. *Arthritis Rheum* 2012; 64: 3083–3094.
37. Totaro MC, Cattani P, Ria F, *et al.* *Porphyromonas gingivalis* and the pathogenesis of rheumatoid arthritis: analysis of various compartments including the synovial tissue. *Arthritis Res Ther* 2013; 15: R66.
38. Okada M, Kobayashi T, Ito S, *et al.* Antibody responses to periodontopathic bacteria in relation to rheumatoid arthritis in Japanese adults. *J Periodontol* 2011; 82: 1433–1441.
39. Seror R, Le Gall-David S, Bonnaure-Mallet M, *et al.* Association of anti-*Porphyromonas gingivalis* antibody titers with nonsmoking status in early rheumatoid arthritis: results from the prospective French cohort of patients with early

- rheumatoid arthritis. *Arthritis Rheumatol* 2015; 67: 1729–1737.
40. de Smit M, Westra J, Vissink A, *et al.* Periodontitis in established rheumatoid arthritis patients: a cross-sectional clinical, microbiological and serological study. *Arthritis Res Ther* 2012; 14: R222.
  41. Eriksson K, Nise L, Kats A, *et al.* Prevalence of periodontitis in patients with established rheumatoid arthritis: a Swedish population-based case-control study *PLoS ONE* 2016; 11: e0155956.
  42. de Pablo P, Dietrich T, Chapple IL, *et al.* The autoantibody repertoire in periodontitis: a role in the induction of autoimmunity to citrullinated proteins in rheumatoid arthritis? *Ann Rheum Dis* 2014; 73: 580–586.
  43. Janssen KM, de Smit MJ, Brouwer E, *et al.* Rheumatoid arthritis-associated autoantibodies in non-rheumatoid arthritis patients with mucosal inflammation: a case-control study. *Arthritis Res Ther* 2015; 17: 174.
  44. Hajishengallis G. Periodontitis: from microbial immune subversion to systemic inflammation. *Nat Rev Immunol* 2015; 15: 30–44.
  45. de Oliveira Ferreira R, de Brito Silva R, Magno MB, *et al.* Does periodontitis represent a risk factor for rheumatoid arthritis? A systematic review and meta-analysis. *Ther Adv Musculoskelet Dis*. Epub ahead of print 9 July 2019. DOI: 10.1177/1759720X19858514.
  46. Reichert S, Schlumberger W, Dähnrich C, *et al.* Association of levels of antibodies against citrullinated cyclic peptides and citrullinated  $\alpha$ -enolase in chronic and aggressive periodontitis as a risk factor of rheumatoid arthritis: a case control study. *J Transl Med* 2015; 13: 283.
  47. Hensvold AH, Frisell T, Magnusson PK, *et al.* How well do ACPA discriminate and predict RA in the general population: a study based on 12,590 population-representative Swedish twins. *Ann Rheum Dis* 2016; 76: 119–125.
  48. Hense S, Luque Ramos A, Callhoff J, *et al.* Prevalence of rheumatoid arthritis in Germany based on health insurance data: regional differences and first results of the PROCLAIR study. *Z Rheumatol* 2016; 75: 819–827.
  49. Donahue KE, Jonas DE, Hansen RA, *et al.* *Drug therapy for rheumatoid arthritis in adults: an update*. Report no. 12-EHC025-EF, April 2012. Rockville (MD): AHRQ Comparative Effectiveness Reviews.
  50. Nielen MM, van Schaardenburg D, Reesink HW, *et al.* Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. *Arthritis Rheum* 2004; 50: 380–386.
  51. Klareskog L, Stolt P, Lundberg K, *et al.* A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. *Arthritis Rheum* 2006; 54: 38–46.
  52. Fisher BA, Cartwright AJ, Quirke AM, *et al.* Smoking, *Porphyromonas gingivalis* and the immune response to citrullinated autoantigens before the clinical onset of rheumatoid arthritis in a Southern European nested case-control study. *BMC Musculoskelet Disord* 2015; 16: 331.
  53. Lahiri M, Morgan C, Symmons DP, *et al.* Modifiable risk factors for RA: prevention, better than cure? *Rheumatology (Oxford)* 2012; 51: 499–512.
  54. Amaral CdSF, da Silva-Boghossian CM, Leão AT, *et al.* Evaluation of the subgingival microbiota of alcoholic and non-alcoholic individuals. *J Dent* 2011; 39: 729–738.
  55. Shanker J, Setty P, Arvind P, *et al.* Relationship between periodontal disease, *Porphyromonas gingivalis*, peripheral vascular resistance markers and coronary artery disease in Asian Indians. *Thromb Res* 2013; 132: e8–e14.
  56. Sochalska M and Potempa J. Manipulation of neutrophils by *Porphyromonas gingivalis* in the development of periodontitis. *Front Cell Infect Microbiol* 2017; 7: 197.
  57. Needleman I, Ashley P, Fine P, *et al.* Oral health and elite sport performance. *Br J Sports Med* 2015; 49: 3–6.
  58. Könönen E, Paju S, Pussinen PJ, *et al.* Population-based study of salivary carriage of periodontal pathogens in adults. *J Clin Microbiol* 2007; 45: 2446–2451.
  59. Southerland JH, Taylor GW and Offenbacher S. Diabetes and periodontal infection: making the connection. *Clinical Diabetes* 2005; 23: 171–178.
  60. Zhang X, Zhang D, Jia H, *et al.* The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment. *Nat Med* 2015; 21: 895–905.
  61. Mättö J, Saarela M, Alaluusua S, *et al.* Detection of *Porphyromonas gingivalis* from saliva by PCR by using a simple sample-processing method. *J Clin Microbiol* 1998; 36: 157–160.
  62. Blicher B, Joshipura K and Eke P. Validation of self-reported periodontal disease: a systematic review. *J Dent Res* 2005; 84: 881–890.